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The topic of this issue’s theme is opportunistic invasive fun-
gal infections (IFIs) in paediatrics. Is there a need to have a
separate theme on paediatric IFIs in the Journal? The short
answer is yes. Children are not little adults. There are
distinct age-related differences in the epidemiology and
pathophysiology of fungal infections, as well as in antifungal
pharmacology in particular. Although the most frequent IFIs,
such as candidiasis and aspergillosis, can occur at all ages,
there are important differences in the frequencies of particu-
lar IFIs, and in the approaches by which they are diagnosed
and treated. Indeed, there are important differences even
between neonates and children in the pharmacokinetics of
certain antifungal agents, as shown in recent years. Further-
more, there is a paucity of data on the optimal use of
common antifungal agents, such as amphotericin B and
ﬂuconazole, in children and especially in neonates.
We have the honour and pleasure to host four excellent
reviews in this issue of the Journal, covering the main areas
of interest in IFIs of paediatric patients. The ﬁrst review
addresses the epidemiology of IFIs in neonates and children,
which is, in some repects, very different from that in adults.
Different underlying risk factors (i.e. prematurity, type of
haematological malignancy, and congenital immunodeﬁcien-
cies) and increasingly diverse spectra of causative species of
fungi (i.e. more frequent Candida parapsilosis in neonates
and more frequent Candida glabrata in adult haematological
patients) with different pathogenicity and mortality have
raised more questions about the management of IFIs in
neonates and children. These questions have made even
more challenging the state-of-the-art care of IFIs in young
patients.
The second article is a comprehensive review of the
non-culture diagnostic methods for IFIs and their current
problems, particularly in neonates and children. Early recog-
nition and rapid initiation of effective treatment is a prerequi-
site for successful management of children with IFIs.
As culture methods are not helpful in many cases, immuno-
diagnostic and molecular methods have been developed.
The third review discusses the issue of IFIs in congenital
immunodeﬁciencies, a particular paediatric group of diseases.
Both acquired and congenital immunodeﬁciencies may be
associated with increased susceptibility to IFIs, depending on
the type of immune deﬁcit. Invasive aspergillosis is the most
frequent cause of death in patients with chronic granuloma-
tous disease. A number of diagnostic and therapeutic speciﬁ-
cations differentiate the management of IFIs in these patients
from that in haematological patients of similar age.
The last review is an excellent update on the pharmaco-
kinetics, safety and dosing of antifungal agents in paediatric
patients, as well as the clinical indications and therapies uti-
lized to manage IFIs in neonates and children. Indeed, the
sequence from neonate to adolescent and to adult involves
many changes in the systematic antifungal therapy, such as
dosing (frequently, larger doses are needed than in adults)
and pharmaceutical formulations (oral solutions rather than
capsules). However, the greatest problem in antifungal ther-
apy in neonates and children is the lack of data on efﬁcacy
and safety in these ages. During the past decade, several new
antifungal agents have been developed. Historically, the large
trials have excluded young patients because of exactly these
potential differences. These advances have also made the
management of IFIs in neonates and children more challeng-
ing, requiring special knowledge and effort. Recently, Pediat-
ric Investigation Plans for some older antifungals have been
developed by the European Medicines Agency, and are
expected to help paediatric antifungal research. Although not
all of the newer agents are yet approved for children, the
development of antifungal agents for paediatric use has
moved forwards in a rapid manner. Although the availability
of new therapeutic options is an important advance, anti-
fungal therapy has become increasingly complex, and a thor-
ough understanding of the available antifungal armamentarium
is essential for optimal therapy of the individual patient.
These and several other issues are raised and discussed in
the comprehensive reviews of this theme. We feel fortunate
to be able to introduce these excellent articles, which we
are sure will be beneﬁcial to the readership of the Journal.
Paediatric IFIs have started to attract considerable interest,
from both the clinical and research points of view, because
of their poor outcome and unfortunate sequelae for young
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patients with a long life-expectancy. Multicentre and, indeed,
multinational collaborative consortia, such as the International
Pediatric Fungal Network (http://pfn.pediatrics.duke.edu) and
the European Society of Paediatric Infectious Diseases Fungal
Study Group, are expected to greatly help in conducting
valuable epidemiological surveys as well as management stud-
ies in neonatal and paediatric patients in the near future. As
the ﬁeld of paediatric mycology advances, we believe that
the next special issue on paediatric IFIs will highlight new
advances in the diagnosis and treatment of these devastating
diseases.
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